RxDoctor Payments Data

Emily Miller

Family · Butler, NJNPI 1104283431

Payments from drug & device makers

$2,546in general payments, 2019–2025

Across 100 payments — averaging $25.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$994
  • AbbVie$433
  • AstraZeneca$342
  • Pfizer$200
  • Novartis$194
  • Johnson & Johnson$134
  • plus $249 from 6 others

What the payments were for

  • Food & beverage$2,42295%
  • Education$1245%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,546 in reported general payments places this provider in the 85th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$165,637
Medicare patients
541
Services billed
3,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept58$492,184
EnbrelEtanercept21$230,219
Humira(Cf)Adalimumab23$153,424
RinvoqUpadacitinib14$88,129
Xeljanz XrTofacitinib Citrate15$86,109
Cosentyx (2 Syringes)Secukinumab12$85,098
Teriparatide16$65,321
ForteoTeriparatide12$50,772
TymlosAbaloparatide12$36,232
ProliaDenosumab20$36,073
MethotrexateMethotrexate Sodium276$8,648
Hydroxychloroquine Sulfate147$6,941
Diclofenac Potassium39$4,868
Prednisone379$3,864
Diclofenac Sodium161$3,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Prolia$994$266,29241 claims
AbbVieHumira(Cf), Rinvoq$433$241,55437 claims
NovartisCosentyx (2 Syringes)$194$85,09812 claims
Radius Health, Inc.Tymlos$63$36,23212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,692 family providers in New Jersey.

Other family in Butler

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →